Strong clinical results, including significant reductions in liver fat, improvements in glycemic control, and fibrosis regression without worsening of NASH, support the efficacy and potential of EFX.
BOSTON--(BUSINESS WIRE)--Acurian Inc., a leading full-service provider of global patient enrollment and retention solutions, and Synexus, the leading global network of dedicated research sites, have ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback